Skip to main content
Article thumbnail
Location of Repository

Fast Fourier Transform and Dynamic Imaging of Caveolar Complex Arrays in Active Striated Muscle

By Kimberley Hazel Smith


Appendix 2: Movie Clips is supplied as a Zip Archive and will need to be unzipped before viewing.The mechanism of force transfer from contracting sarcomeres to the membrane and endomysium of striated muscle fibres is unclear. The caveolar complex array in striated muscle membranes is a local concentration of cholesterol, sphingomyelin, signalling molecules and the protein caveolin-3. Immunofluorescence microscopy of caveolin-3 in the membrane reveals a regular pattern of fluorescent nodes arranged in longitudinal and transverse rows. The primary aim of this study was to analyse this pattern and how caveolin-3 behaves during contraction. Dynamic imaging and Fast Fourier Transforms (FFTs) were used to study force transmission across the fibre membrane. \ud This pattern was studied in frozen sections of both shortened and rest-length striated muscle fibres. Direct and FFT measurements of spacings between these nodes demonstrated significant reductions in longitudinal measurements in shortened muscle when compared to rest-length muscle. Caveolin-3 nodes lay in register with underlying actin bands in both muscle states, and co-localised with dystrophin. Caveolin-3 was not detectable in C2C12 myoblasts. During differentiation expression became detectable at 2 days. Caveolin-3 was present during myoblast fusion, before forming the regular pattern on the membrane from days 4-5. Fibres became contractile after 5-6 days of development. By 12 days, muscle fibres are 1-2 mm long, multinucleated myotubes with evidence of the caveolin-3 immunofluorescence pattern seen in mature fibres. Knockdown of caveolin-3 expression greatly reduced the number of differentiated myotubes at 12 days. This pattern was not demonstrated in contracting myotubes, possibly owing to lack of permeability to the antibody. \ud The results are consistent with the hypothesis that the force of contraction is transferred across the whole membrane rather than at fibre distal ends

Publisher: University of Leicester
Year: 2010
OAI identifier:

Suggested articles


  1. (2003). A CAV3 microdeletion differentially affects skeletal muscle and myocardium.
  2. (1974). A core-conductor model of the cardiac Purkinje fibre based on structural analysis.
  3. (2006). A fibronectin-binding protein from Streptococcus equi binds collagen and modulates cellmediated collagen gel contraction.
  4. (2000). A molecular dissection of caveolin-1 membrane attachment and oligomerization.
  5. (2006). A new paradigm for membrane-organizing and -shaping scaffolds.
  6. (2004). A novel mutation in the caveolin-3 gene causing familial isolated hyperCKaemia.
  7. (1996). A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane.
  8. (1999). A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1.
  9. (1975). A textbook of Histology.
  10. (1976). A three-dimensional reconstruction of the polygonal pattern on placental coated-vesicle membranes.
  11. (2007). Accelerated de novo sarcomere assembly by electric pulse stimulation in C2C12 myotubes.
  12. (1995). Acetylcholine-activated inward current induces cytosolic Ca 2+ mobilization in mouse C2C12 myotubes.
  13. (1999). Activation of store-operated Ca 2+ current in Xenopus oocytes requires SNAP-25 but not a diffusible messenger.
  14. (2008). Actomyosin interaction: Mechanical and energetic properties in different nucleotide binding states.
  15. (2006). Altered caveolin-3 expression disrupts PI(3) kinase signaling leading to death of cultured muscle cells.
  16. (1974). An ultrahistochemical study on glycogen in cow Purkinje fibres.
  17. (2000). Assembly of Trp1 in a signaling complex associated with caveolin-scaffolding lipid raft domains.
  18. (1998). Assessment of strain field in endothelial cells subjected to uniaxial deformation of their substrate.
  19. (2006). Autonomic regulation of voltage-gated cardiac ion channels.
  20. (1994). C2C12 Cells: biophysical, biochemical and immunocytochemicial properties.
  21. (2004). C2C12 co-culture on a fibroblast substratum enables sustained survival of contractile, highly differentiated myotubes with peripheral nuclei and adult fast myosin expression.
  22. (1994). Ca 2+ signalling pathways activated by acetylcholine in mouse C2C12 myotubes. Pflügers Archiv European Journal of Physiology.
  23. (2008). Calcium extrusion by plasma membrane calcium pump is impaired in caveolin-1 knockout mouse small intestine.
  24. (1999). Calcium influx factor is synthesized by yeast and mammalian cells depleted of organellar calcium stores.
  25. (1993). Calcium pump of the plasma membrane is localized in caveolae.
  26. (2006). Calcium-independent phospholipase A2 modulates cytosolic oxidant activity and contractile function in murine skeletal muscle cells.
  27. (1983). Cardiac Purkinje cells in culture.
  28. (2001). cav-p60 expression in rat muscle tissues. Distribution of caveolar proteins.
  29. (2002). Caveolae and caveolin in immune cells: distribution and functions.
  30. (2001). Caveolae and intracellular trafficking of cholesterol.
  31. (2006). Caveolae and the endotherlial nitric oxide synthase.
  32. (2002). Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking.
  33. (2008). Caveolae as organizers of pharmacologically relevant signal transduction molecules.
  34. (1999). Caveolae require intact VAMP for targeted transport in vascular endothelium.
  35. (2003). Caveolae-associated proteins in cardiomyocytes: caveolin-2 expression and interactions with caveolin-3.
  36. (1997). Caveolae, DIGS, and the dynamics of sphingolipid-cholesterol microdomains.
  37. (2001). Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissuespecific drug and gene delivery in vivo.
  38. (2002). Caveolae: From cell biology to animal physiology.
  39. (2005). Caveolae: Stable membrane domains with a potential for internalization.
  40. (2003). Caveolae/raft-dependent endocytosis.
  41. (2006). Caveolin and its role in intracellular chaperone complexes.
  42. (1999). Caveolin is an inhibitor of platelet-derived growth factor receptor signaling.
  43. (1995). Caveolin is palmitoylated on multiple cytosine residues.
  44. (2005). Caveolin isoform expression during differentiation of C6 glioma cells.
  45. (1995). Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution.
  46. (1994). Caveolin moves from caveolae to the golgi apparatus in response to cholesterol oxidation.
  47. (1997). Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers.
  48. (2000). Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy.
  49. Caveolin-1 expression is down-regulated in cells transformed by the Human Papilloma Virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation.
  50. (2005). Caveolin-1 is not required for murine intestinal cholesterol transport.
  51. (2000). Caveolin-1 isoforms are encoded by distinct mRNAs.
  52. (2006). Caveolin-1 mutations in human breast cancer. Functional association with estrogen receptor α-positive status.
  53. (2002). Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities.
  54. (2001). Caveolin-2 is targeted to lipid droplets, a new “membrane domain” in the cell.
  55. (1999). Caveolin-2 localizes to the Golgi complex but redistributes to plasma membrane, caveolae, and rafts when co-expressed with caveolin-1.
  56. (2002). Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae.
  57. (1997). Caveolin-3 associates with developing Ttubules during muscle differentiation.
  58. (2000). Caveolin-3 deficiency causes muscle degeneration in mice.
  59. (1999). Caveolin-3 Is associated with the T-tubules of mature skeletal muscle fibers.
  60. (1998). Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
  61. (2001). Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and T-tubule abnormalities.
  62. (1999). Caveolin-3 upregulation activates β-secretase–mediated cleavage of the amyloid precursor protein in Alzheimer‟s disease.
  63. (2004). Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic.
  64. (1992). Caveolin, a protein component of caveolae membrane coats.
  65. (2005). Caveolin, cholesterol, and lipid bodies.
  66. (2005). Caveolin; different roles for insulin signal?
  67. (2003). Caveolin: A key target for modulation nitric oxide availability in health and disease.
  68. (2004). Caveolinopathies: Mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases.
  69. (2007). Caveolins in glial cell model systems: from detection to significance.
  70. (1998). Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane.
  71. (2003). Cell and molecular mechanics of biological materials. nature materials,
  72. (1984). Cell type-specific activation of actin genes in the early amphibian embryo.
  73. (1997). Cell-type and tissue-specific expression of caveolin-2.
  74. (1990). Cellular and biochemical aspects of muscle differentiation.
  75. (2007). Cellular spelunking: exploring adipocyte caveolae.
  76. (1998). Characterization of a cytosolic heat-shock protein-caveolin chaperone complex.
  77. (2001). Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control.
  78. (2002). Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid-protein complex.
  79. (1998). Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3).
  80. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
  81. (2003). Coating and selective deposition of nanofilm on silicone rubber for cell adhesion and growth.
  82. (2003). Concentration of caveolin-3 at the neuromuscular junction in young and old rat skeletal muscle fibers.
  83. (1993). Confocal and conventional immunofluorescence and ultrastructural localisation of intracellular strength-giving components of human amniochorion.
  84. (1992). Confocal laser microscopy of dystrophin localization in guinea pig skeletal muscle fibers.
  85. (2001). Contractile activity-induced transcriptional activation of cytochrome c involves Sp1 and is proportional to mitochondrial ATP synthesis in C2C12 muscle cells.
  86. (2008). Contractile C2C12 myotube model for studying exercise-inducible responses in skeletal muscle.
  87. (2004). Contractile skeletal muscle tissue-engineered on an acellular scaffold. Plastic and Reconstructive Surgery,
  88. (2008). Cooperative synergy between NFAT and MyoD regulates myogenin expression and myogenesis.
  89. (1996). Copurification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains.
  90. (1998). Crowded little caves: Structure and function of caveolae.
  91. (2003). Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer‟s and dementia with Lewy bodies.
  92. (1995). De novo Formation of Caveolae
  93. (2004). Design and performance of an electrical stimulator for long-term contraction of cultured muscle cells.
  94. (1994). Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae.
  95. (1996). Detergentresistant membrane microdomains from Caco-2 cells do not contain caveolin.
  96. (1977). Differentiated regions of human placental cell surface associated with exchange of materials between maternal and foetal blood: Coated vesicles.
  97. (1987). Differentiation and innervation of the atrioventricular bundle and ventricular Purkinje system in sheep heart.
  98. (1967). Differentiation of the sarcoplasmic reticulum and T system in developing chick skeletal muscle in vitro.
  99. (1992). Direct visualization of the dystrophin network on skeletal muscle fiber membrane.
  100. (2006). Disruption of MEF2 activity in cardiomyoblasts inhibits cardiomyogenesis.
  101. (2000). Dissociation of the distroglycan complex in caveolin-3 deficient limb girdle muscular dystrophy.
  102. (2000). Distinct patterns of dystrophin organization in myocyte sarcolemma and Transverse tubules of normal and diseased human myocardium.
  103. (1988). Duchenne Muscular Dystrophy: Deficiency of dystrophin at the muscle cell surface.
  104. (1981). Dynamic aspects of structural proteins in vertebrate skeletal muscle.
  105. (1998). Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium.
  106. (1998). Dynamin-mediated internalization of caveolae.
  107. (2003). Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and
  108. (2000). Dystrophin associates with caveolae of rat cardiac myocytes. Relationship to dystroglycan.
  109. (1987). Dystrophin: The protein product of the Duchenne Muscular Dystrophy locus.
  110. (1993). Dystrophinglycoprotein complex and laminin colocalize to the sarcolemma and Transverse tubules of cardiac muscle.
  111. (2002). Early signals in cardiac development.
  112. (2005). Early-onset toe walking in rippling muscle disease due to a new caveolin-3 gene mutation.
  113. (2005). Effects of stretching stress in the muscle contraction proteins of skeletal muscle myoblasts.
  114. (2004). Effects of α1-adrenergic stimulation on normal and hypertrophied mouse hearts. Relation to caveolin-3 expression.
  115. (1997). Electrical stimulation of C2C12 myotubes induces contractions and represses thyroid-hormone-dependent transcription of the fast-type sarcoplasmic-reticulum Ca2+-ATPase gene.
  116. (2007). Electron microscope tomography: further demonstration of nanocontacts between caveoale and smooth muscle sarcoplasmic reticulum.
  117. (2004). Electroporation-mediated delivery of molecules to model intestinal epithelia.
  118. (2003). Electrotransfection of anchorage-dependent mammalian cells.
  119. (1998). Elevated expression of caveolin is associated with prostate and breast cancer.
  120. (1989). Embryonic induction and muscle gene activation.
  121. (1999). Embryonic stem cell differentiation models: cardiogenesis, myogenesis, neurogenesis, epithelial and vascular smooth muscle cell differentiation in vitro.
  122. (1993). Emptying of intracellular Ca 2+ stores releases a novel small messenger that stimulates Ca 2+ influx.
  123. (2002). Endocytosis via caveolae.
  124. (1979). Endothelial plasmalemmal vesicles as elements in a system of branching invaginations from the cell surface.
  125. (1985). Endothelial plasmalemmal vesicles have a characteristic striped bipolar surface structure.
  126. (2001). Endothelial transcytotic machinery involves supramolecular protein–lipid complexes.
  127. (2001). Evaluation of the dystrophin-glycoprotein complex, α-actinin, dysferlin and calpain 3 in an autosomal recessive muscular dystrophy in Labrador retrievers.
  128. (2001). Excitability and contractility of skeletal muscle engineered from primary cultures and cell lines.
  129. (1996). Expression of caveolin-3 in skeletal, cardiac, and smooth Muscle Cells.
  130. (2008). Expression of the muscular dystrophy-associated caveolin-3 P104L mutant in adult mouse skeletal muscle specifically alters the Ca 2+ channel function of the dihydropyridine receptor. Pflügers Archiv -
  131. (2006). Familial idiopathic hyper-CK-emia: An underrecognized condition.
  132. (1976). Filament systems in Purkinje cells of the sheep heart: Possible alterations of myofibrillogenesis.
  133. (1994). Filipin-sensitive caveolae-mediated transport in endothelium: Reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules.
  134. (1953). Fine structure of blood capillaries.
  135. (1968). Formation of elaborate networks of T-system tubules in cultured skeletal muscle with special reference to the T-sytem formation.
  136. (1992). Formation of skeletal muscle in vivo from the mouse C2 cell line.
  137. (1981). Freeze-fracture studies of muscle caveolae in human muscular dystrophy.
  138. (2003). Function of caveolae in Ca 2+ entry and Ca 2+ -dependent signal transduction.
  139. (1998). Functions of lipid rafts in biological membranes.
  140. (2005). G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes.
  141. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
  142. (2007). gene expression at different stages of skeletal myogenesis.
  143. (2000). Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2.
  144. (1995). Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin.
  145. (2002). GRGDSP peptide-bound silicone membranes withstand mechanical flexing in vitro and display enhanced fibroblast adhesion.
  146. (2006). HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage.
  147. (2006). Hedgehog acts directly on the zebrafish dermomyotome to promote myogenic differentiation.
  148. (2000). High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitricoxide synthase localization and activation in caveolae.
  149. (2007). homeostasis of single smooth muscle cells from rat cerebral resistance arteries.
  150. (2009). Human embryonic stem cells and cardiac repair.
  151. (2007). Hypertrophy and atrophy inversely regulate caveolin-3 expression in myoblasts.
  152. (2004). Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy.
  153. (2002). Identification of a splice variant of mouse caveolin-2 mRNA encoding an isoform lacking the C-terminal domain.
  154. (1997). Identification of caveolin and caveolin-related proteins in the brain.
  155. (1999). Identification of caveolin-1 as a fatty acid binding protein.
  156. (1997). Identification of peptide and protein ligands for the caveolin-scaffolding domain.
  157. (1996). Identification, sequence, and expression of caveolin-2 defines a caveolin gene family.
  158. (2004). in muscle cell differentiation.
  159. (2004). Increased caveolin-1 expression in Alzheimer‟s disease brain.
  160. (1998). Increased caveolin-3 levels in mdx mouse muscles.
  161. (1999). Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy.
  162. (2005). Increased permeability of intestinal epithelial monolayers mediated by electroporation.
  163. Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles.
  164. (2001). Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase. Implications for vascular disease.
  165. (2004). Insulin resistance in skeletal muscles of caveolin-3-null mice.
  166. (1982). Intracellular calcium translocation during contraction in vertibrate and invertebrate smooth muscle as studied by the pyronantinonate method.
  167. (2002). Involvement of caveolae and caveolae-like domains in signalling cell survival and angiogenesis.
  168. (2000). Involvement of cellular caveolae in bacterial entry into mast cells.
  169. (2006). Involvement of lipid rafts and caveolae in cardiac ion channel function.
  170. JR (1992a). The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles.
  171. (2004). Limb-girdle muscular dystrophies - from genetics to molecular pathology.
  172. (2000). Lipid rafts and signal transduction.
  173. (2006). Lipid rafts, caveolae and membrane traffic.
  174. lipid rafts: G protein-coupled receptor signaling microdomains in cardiac myocytes.
  175. (2006). Localization of cardiac Ltype Ca 2+ channels to a caveolar macromolecular signaling complex is required for β2-adrenergic regulation.
  176. (1992). Localization of inositol 1,4,5-trisphosphate receptor-like protein in plasmalemmal caveolae.
  177. (1999). Localization of the human caveolin-3 gene to the D3S18/D3S4163/D3S4539 locus (3p25), in close proximity to the human oxytocin receptor gene.
  178. (1999). Localization of the insulin receptor in caveolae of adipocyte plasma membrane.
  179. (2004). Long-chain fatty acid uptake into adipocytes depends on lipid raft function.
  180. (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.
  181. (2006). Loss of filaminC (FLNc) results in severe defects in myogenesis and myotube structure.
  182. (2009). Low dose simvastatin induces compositional, structural and dynamical changes on rat skeletal extensor digitorum longus muscle tissue.
  183. (1995). M-caveolin, a muscle-specific caveolin-related protein.
  184. (2008). Magnitude of sarcomere extension correlates with initial sarcomere length during lengthening of activated single fibers from soleus muscle of rats.
  185. (2001). Mechanical stretch is a down-regulatory signal for differentiation of C2C12 myogenic cells.
  186. (2002). Mechanism of caveolin filament assembly.
  187. (2000). Membrane binding of peptides containing both basic and aromatic residues. Experimental studies with peptides corresponding to the scaffolding region of caveolin and the effector region of MARCKS.
  188. (1999). Modulation of Ca entry.
  189. (2002). Molecular cloning and developmental expression of the caveolin gene family in the amphibian Xenopus laevis.
  190. (1996). Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle.
  191. (2005). Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources.
  192. (1989). Motor unit organisation in developing muscle. Comparative Biochemistry and Physiology A - Comparative Physiology,
  193. (2000). Multiple domains in caveolin-1 control its intracellular traffic.
  194. (1997). Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is Nglycosylated and fatty acylated and colocalizes with plasma membrane caveolae.
  195. (1993). Muscle Contraction:
  196. (1969). Muscle fibre growth in five different muscles in both sexes of mice. I. Normal mice.
  197. (2005). Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs. muscle cells.
  198. (2009). Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation.
  199. (2008). MyoD targets TAF3/TRF3 to activate myogenin transcription.
  200. (1989). Myogenic cell lineages: Commitment and modulation during differentiation of avian muscle.
  201. (2008). Myostatin is a procachectic growth factor during postnatal myogenesis.
  202. (1995). Myristoylation and differential palmitoylation of the HCK protein-tyrosine kinases govern their attachment to membranes and association with caveolae.
  203. (2008). Na +–K+ pump location and translocation during muscle contraction in rat skeletal muscle. Pflügers Archiv European
  204. (1988). Normal and dystrophindeficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy.
  205. (2004). Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.
  206. (1989). Novel tyrosine kinase substrates from Rous sarcoma virustransformed cells are present in the membrane skeleton.
  207. (2006). Nuclear envelope transmembrane proteins (NETs) that are up-regulated during myogenesis.
  208. (1995). Oligomeric structure of caveolin: Implications for caveolae memebrane organization.
  209. (1996). Oligomerization of VIP21-caveolin in vitro is stabilized by long chain fatty acylation or cholesterol.
  210. (2004). Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity.
  211. (1999). Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation.
  212. (1975). Permeability of muscle capillaries to small heme-peptides: Evidence for the existence of patent transendothelial channels.
  213. (2007). Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophy-related caveolin-3 P104L and TFT mutants.
  214. (1999). Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD1C).
  215. (1996). Phosphorylation of caveolin by Src tyrosine kinases.
  216. (1980). Pinocytotic function of the membrane vesicles, or caveolae, in heart muscle cells.
  217. (2009). Plasma membrane removal in rat skeletal muscle fibers reveals caveolin-3 hot-spots at the necks of transverse tubules.
  218. (1985). Plasticity of the differentiated state.
  219. (1992). Potocytosis: sequestration and transport of small molecules by caveolae.
  220. (2006). Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and δ-opioid receptors.
  221. (2004). Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes.
  222. (1994). Purification and characterization of smooth muscle cell caveolae.
  223. (1976). Quantitative morphological study of smooth muscle cells of the guinea-pig taenia coli.
  224. (1997). Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorageindependent growth.
  225. (2002). Reduction in intracellular calcium levels inhibits myoblast differentiation.
  226. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells.
  227. (2005). Regulated localization of Rab18 to lipid droplets.
  228. (2001). Review of Medical Physiology.
  229. (2005). Rippling muscle disease may be caused by "silent" action potentials in the tubular system of skeletal muscle fibers.
  230. (2006). RNA interference: Mechanisms of action and therapeutic consideration.
  231. (2003). Role of caveolae in signal-transducing function of cardiac Na -ATPase.
  232. (2006). Role of caveolin-1 and cholesterol in transmembrane fatty acid movement.
  233. (2004). Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation.
  234. (2000). Role of cholesterol in developing Ttubules: Analogous mechanisms for T-tubule and caveolae biogenesis.
  235. (1998). Role of plasmalemmal caveolae in signal transduction.
  236. (1971). Satellite cells as the source of nuclei in muscles of growing rats.
  237. (2005). Secrets of caveolae- and lipid raft-mediated endocytosis revealed by mammalian viruses.
  238. (1992). Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virustransformed fibroblasts.
  239. (1977). Serial passaging and differentiation of myogeinc cells isolated from dystrophic mouse muscle.
  240. (1993). Signal transducing molecules and Glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells.
  241. (2003). Simultaneous imaging and functional assessment of cytoskeletal protein connections in passively loaded single muscle cells.
  242. (2008). Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway.
  243. (1975). Size and shape of transverse tubule openings in frog twitch muscle fibers.
  244. (1975). Sizes of components in frog skeletal muscle measured by methods of stereology.
  245. (2004). Skeletal muscle function: Role of ionic changes in fatigue, damage and disease.
  246. (1997). SNARES and NSF in targeted membrane fusion.
  247. (1986). Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: Receptor-mediated transcytosis.
  248. (2005). Sphingosine 1-phosphate regulates myogenic differentiation: a major role for S1P2 receptor.
  249. (2006). Statin-induced apoptosis and skeletal myopathy.
  250. (2004). Stretch activation of GTP-binding proteins in C2C12 myoblasts.
  251. (2001). Stretching and fibroblast growth on GRGDSP-peptide modified silicone membranes.
  252. (2005). Structure of caveolae.
  253. (2007). T-tubule profiles in Purkinje fibres of mammalian myocardium.
  254. (2007). Target gene selectivity of the myogenic basic helix–loop–helix transcription factor myogenin in embryonic muscle.
  255. (1999). Targeted downregulation of caveolin-3 Is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts.
  256. (1997). Techniques of advanced light microscopy and their applications to morphological analysis of human extra-embryonic membranes.
  257. (2000). The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development.
  258. (2007). The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
  259. (2002). The cardiac sodium-calcium exchanger associates with caveolin-3. Annals of The New York Academy of Sciences,
  260. (2002). The distribution of caveolin-3 immunofluorescence in skeletal muscle fibre membranes defined by dual channel confocal laser scanning microscopy, fast Fourier transform and image modelling.
  261. (2004). The dystrophin glycoprotein complex: signalling strength and integrity for the sarcolemma.
  262. (2002). The dystrophin-associated protein complex.
  263. (1998). the exocytic pathway of MDCK cells.
  264. (1955). The fine structure of the gall bladder epithelium of the mouse.
  265. (1972). The fluid mosaic model of the structure of cell membranes.
  266. (1999). The membrane-spanning domains of caveolins-1 and -2 mediate the formation of caveolin hetero-oligomers.
  267. (2002). The molecular architecture of calcium microdomains in rat cardiomyocytes.
  268. (1975). The relative contributions of the folds and caveolae to the surface membrane of frog skeletal muscle fibres at different sarcomere lengths.
  269. (2006). The role of caveolae and noncaveolar rafts in endocytosis.
  270. (1993). The role of macrophages in skeletal muscle regeneration with particular reference to chemotaxis.
  271. (2002). The scaffolding domain of caveolin 2 is responsible for its golgi localization in Caco-2 cells.
  272. (1972). The surface area of sheep cardiac Purkinje fibres.
  273. (1966). The variation in isomeric tension with sarcomere length in vertebrate muscle fibres.
  274. (1976). The ventricular conduction system - Ultrastructure and function.
  275. (1981). Theory and Practice of Histotechnology: The C.V.
  276. (1993). Thy-1 glycoprotein and src-like protein-tyrosine kinase p53/p56 lyn are associated in large detergent-resistant complexes in rat basophilic leukemia cells.
  277. (1998). Transcytosis of α1-acidic glycoprotein in the continuous microvascular endothelium.
  278. (1992). Transendothelial transport of serum albumin: A quantitative immunocytochemical study.
  279. (1989). Transferrin as a muscle trophic factor.
  280. (2003). Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype.
  281. (1996). Transport of insulin and albumin by the microvascular endothelium of the rete mirabile.
  282. (2005). Triacylglycerol is synthesized in a specific subclass of caveolae in primary adipocytes.
  283. (1998). Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells.
  284. (1997). Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol.
  285. (1999). Tyrosine phosphorylation of caveolin-1 in the endothelium.
  286. (2004). Tyrosine phosphorylation of caveolin-2 at residue 27: Differences in the spatial and temporal behavior of phospho-cav-2 (pY19 and pY27).
  287. (2001). Upregulation of caveolin in multidrug resistant cancer cells: functional implications.
  288. (1998). Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells.
  289. (1995). VIP21-Caveolin, a Membrane Protein Constituent of the Caveolar Coat, Oligomerizes In Vivo and In Vitro.
  290. (1992). VIP21, A 21-kD membrane protein is an integral component of trans-golgi-networkderived transport vesicles.
  291. (1983). Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.